

ACURA PHARMACEUTICALS, INC  
Form 8-K  
May 27, 2014

UNITED STATES

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D. C. 20549**

FORM 8-K

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act Of 1934**

**May 27, 2014**

Date of Report (Date of earliest event reported)

**ACURA PHARMACEUTICALS, INC.**  
(Exact Name of Registrant as Specified in Charter)

<b>State of New York</b>	<b>1-10113</b>	<b>11-0853640</b>
(State of Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

616 N. North Court, Suite 120

Palatine, Illinois 60067

(Address of principal executive offices) (Zip Code)

**(847) 705-7709**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d- 2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c))

**Item 8.01 Other Events**

On May 27, 2014 we issued a press release announcing that the US Food and Drug Administration (FDA) advised us that the data from our intranasal abuse liability study AP-ADF-301 (Study 301) for our AVERSION® hydrocodone bitartrate with acetaminophen (hydrocodone/APAP) product candidate are insufficient to support an intranasal abuse deterrence claim and questioned whether the intranasal route is a relevant route of abuse for hydrocodone/APAP products and recommended we identify variables that could have impacted the findings from Study 301 before considering or conducting an additional intranasal abuse liability study on our AVERSION hydrocodone/APAP product. The press release is attached hereto and filed as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits**

**Exhibit Number Description**

99.1	Press Release dated May 27, 2014
------	----------------------------------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ACURA PHARMACEUTICALS, INC.**

By: /s/ Peter A. Clemens  
Peter A. Clemens  
Senior Vice President & Chief Financial Officer

Date: May 27, 2014

**Exhibit Index**

**Exhibit Number Description**

99.1 Press Release dated May 27, 2014